Lipid Nanoparticles Improve Activity of Single-Stranded siRNA and Gapmer Antisense Oligonucleotides in Animals
Thazha P. Prakash(Ionis Pharmaceuticals (United States)), Stanley T. Crooke(Stanley Foundation), Don Foster(Alnylam Pharmaceuticals (United States)), Sayda M. Elbashir(Max Planck Institute for Biophysical Chemistry), Muthusamy Jayaraman(Forma Therapeutics (United States)), Alfred E. Chappell(Ionis Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), William Cantley(Alnylam Pharmaceuticals (United States)), Heather Murray(Ionis Pharmaceuticals (United States)), Walt F. Lima(Ionis Pharmaceuticals (United States)), Eric E. Swayze(Ionis Pharmaceuticals (United States))
Cited by 48
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k